Who is Hands Up For Hooters?
Hands Up For Hooters is a fundraising team from Fair Oaks, CA, raising money for the Susan G. Komen 3-Day Event, held in San Diego November 12-19, 2017. We must each raise $2300 to be able to walk in the event, which entails walking 20 miles each day (yes, each of us), 3 days in a row. Breast cancer survivor Sally Dunbar is the Team Captain, and is responsible for creating and building the team.
Contact info: Sally Dunbar, (916) 524-1548, SDunbar@GoLyon.com
History of Hands Up For Hooters
After walking in 3 separate 3-Day events (Seattle and San Francisco), Fair Oaks Realtor and breast cancer survivor Sally Dunbar wanted to raise more money for the Komen Foundation - more than the $2,300 required. She set an outrageous goal of $100,000, thinking "No great achievement was ever reached without an outrageously huge goal". Doing the math, she decided a team of 45 walkers would yield her 35 actual walkers, after attrition, which would raise $100,000. She started recruiting - friends, co workers, family, strangers in line at the post office, dress shop workers. Honestly, anyone who would listen, and some who didn't want to. The team reached 69, ending with 57 successfully raising their money and walking in the San Diego 3-Day event. Maybe half walked all 20 miles each day. The rest walked what they could, and took the sweep vans in between pit stops. There were many, many tears at the end. The second year we recruited 123 walkers, and beat our goal of $200,000, raising $230,000. This mean that in two years, we have raised $377,000 for the Komen Foundation with the 3-Day Event.
2015 - our first year. Our goal was 45 walkers, raising $100,000. We ended up with 69 walkers, and raised $147,000.
2016 - our second year. Our goal was 100 walkers, raising $200,000. We ended up with 123 walkers, and raised $230,000. We were honored as the largest team walking the San Diego Event, and the most number of NEW 3-Day walkers in Komen history. We were also the 2nd largest Komen team in the entire US.
2017 - Our goal is a hefty $300,000 (whew)
How We Raise Funds
Each walker must raise their own money, preferably by reaching out to their friends and family. Through reaching out, information about breast cancer and its effects on individuals and families is shared. While some Hooters might simply write a check for the amount, it is far more powerful when they spread the word. The average walker will receive 20-25 or so donations, meaning that for 2016, 2000 separate donors supported our mission to end death from breast cancer. Many more heard our information. We are open to corporate sponsorships, ie large chunks of cash!
What Our Walkers Say Afterwards
"There are women and men out there - maybe even our own daughters at some point in time - who will live long lives because of the new treatments and cures that come from the research we are funding." Diane Ullman, Connecticut walker and Education Administrator.
"I lost my mother at 13. If she were diagnosed today, they could have helped her. So my journey in walking is for my kids and their kid's kids, hoping someday soon there will be a cure." Cindy Limbo, Insurance administrator
"What I never expected was the feeling of confidence I now have about other aspects of my life. I am finding myself outside of the 'comfort zone' often." Pat Galeria, retired school teacher
"There are lessons I learned about myself that I will keep with me for the rest of my life. I learned I am pretty powerful when I set my mind to it." Joan Tubbs, mother of breast cancer survivor, who walked with a torn meniscus.
"This will be a year to remember, and a year of gratitude for me. No more I CAN'T DO THIS. This is a year of I CAN!" Kathy Chigbrow, who walked with 50% lung capacity from previous lung disease.
"I didn't expect the impact this would have on my family and friends. The outpouring of love, support, good wishes and appreciation continues to astound me." Paula Turk, nurse.
"It was wonderful to be involved in something so much bigger than me and to do it with such great people." Nicole McKane, Title Insurance Representative.
Hooters in the News
Ed Goldman's Column in the Business Journal, about "Energist" Sally Dunbar, Team Leader of Hands Up For Hooters, May 5, 2017
Good Day Sacramento TV coverage, with Tina Macuha, April 29, 2017
Leadership in Philanthropy Award given to Sally Dunbar, by Lyon Real Estate, April 2017.
Article on Stories of Impact, about individuals and organizations who impacted Komen's goal of lowering deaths from breast cancer by 50% by 2026. Published January 31, 2017.
Blog post about Hands Up For Hooters in 2015, our first year, and how we recruited 65 new walkers. Appeared on the Susan G. Komen Blog, Published December 9, 2015.
Why Do We Support Komen?
Because the Komen Foundation is the largest contributor to breast cancer support/issues in the entire world, next to the US Government. Because of that, any researcher with a serious idea, will come to Komen for funding, meaning they get to analyse the best, the brightest and the most promising budding research. We trust the Komen team of advisors to make the best decision as to where the money will go.
Every major advancement in breast cancer research in recent years has been impacted by a Komen grant.
And because they have created the most fun way to tackle a very serious cause - walking in the 3-Day! Where else can you walk the streets of a major city with traffic cops wearing pink tutus? In the process the walkers get healthier, which lowers each of our risk factors for breast cancer.
Breast Cancer Progress
* Since 1980 the five-year relative survival rate for women diagnosed with early stage breast cancer was about 74 percent. Today, it is 99 percent.
*Since 1990 early detection and effective treatment have resulted in a 34 percent decline in breast cancer mortality in the US.
Breast Cancer Quick Facts
1 in 8 women in the US will be diagnosed in her life with breast cancer.
Breast cancer is the 2nd leading cause of death in women
Each year (as of 2015) 220,000 women and 2,150 men will be diagnosed with breast cancer in US
Wince 1990 Early detection and effective treatment has resulted in 34% decline in breast cancer mortality in US
- Since 1980, the 5 year relative survival rate for women diagnosed with early stage breast cancer has gone from 74% to 99%.
Where Does The Money Go?
Since 1982, Komen has funded more than $847 million in research, more than $1.8 billion in screening, education, treatment and psychosocial support, and served millions in over 30 countries worldwide. This is more than any organization in the world, next to the US government.
Of Komen organization income, in 2013, 83% of total dollars were spent funding the mission of finding a cure and eradicating breast cancer.
75% of Komen proceeds go to research, grants, and large public health outreach programs (this is national and worldwide.)
25% of proceeds go to local community support and outreach (this stays local)
Since 1982, Komen dollars have helped support:
2400 research grants in 49 states and 20 countries
460 clinical trials
300 research advocates
60 partnerships and collaborations
60 scientific conferences
Susan G. Komen Research Efforts
Since 1982 $847 Million has been spent on 2400 Research Grants, and 450 Clinical Trials in 48 states and 21 countries, Including:
$22M in 45 grants and 22 trials in Obesity, Weight and Excercise
$36M in 110 grants and 25 trials in BRCA (breast cancer susceptibility)
$33M in 115 grants and 50 trials in Early Detection
$24M in 75 grants and 30 trials in Complementary Medicine
$60M in 150 grants and 15 trials in HER2
$133M in 350 grants and 35 trials in Metastatic Breast Cancer
$48M in 85 grants and 15 trials in Prevention of Breast Cancer
$80M in 115 grants and 20 trials in Triple Negative Breast Cancer
$25M in 65 grants and 5 trials in Immunotherapy and Vaccines
$158M in 330 grants and 70 trials in Precision Medicine
$36M in 70 grants in Early Detection, diagnostic and Risk Biomarkers
$41M in 100 grants in Prognostic Biomarkers
$66M in 100 grants in Predictive Biomarkers
$45M in 100 grants in Targeted Therapies
$9.5M in 30 grants and 15 trials in Breast Cancer in Young Women
$33M in 80 grants and 20 trials in Nutrition and Breast Cancer
$26M in 80 grants and 30 trials in Hereditary Breast Cancer
Sample Research Grants in California 2015 (a sampling of 122 grants listed, to give you an idea)
UC San Diego: Targeting stem cell niche in aggressive breast cancer
USC: Disruption of the tumor microenvironment in HER2 breast to brain metastases
USC: Nail salon work and mammographic density in Vietnamese Americans
UCSF: Targeting urokinase receptor for diagnosis and therapy of aggressive breast cancers
UCSF: Therapy of triple negative breast cancer by targeting TPXs mitotic regulator
UCSD: Chromosomal enhancer/architectural misregulation in breast cancer
Stanford: PARP inhibition in homologous recombination –deficient breast cancer
UCLA: Stress reduction in breast cancer survivors: intervention development and evaluation
UCSF: MR imaging phenotypes of breast cancer
Stanford: optimizing therapy for early stage triple-negative breast cancer
Salk Institute: Mammary stem cells and breast cancer
Stanford: Measuring circulating tumor cells in vivo for breast cancer metastasis detection
Dr. Susan Love Research Foundation: 8th International symposium on the breast
Misc Grants, 2015:
Duke University: Fibulin-3 as a biomarker and target in the breast tumor
Georgia Tech Research Corp: Breast cancer immunotherapy targeting sentinel lymph nodes
Dana Farber Cancer Institute: Identifying resistance mechanisms in ER+ breast cancer by translational genomics
Georgetown University: Graduate training in breast cancer disparities at Lombardi Cancer Center
Tufts Medical Center: Tufts breast cancer training program to reduce Asian health disparities
Princeton Univ: Ubiquitin-dependent regulation of EMT in metastasis
Duke Univ: ALK4 in suppressing breast cancer progression
Baylor College of Medicine: Clinical identification and regulation of cancer stem cells in TNBC
Johns Hopkins Univ: Cellular and molecular mechanisms of breast cancer invasion
Harvard: Dynamics of cell fate decisions after breast cancer radiotherapy
Vanderbilt Univ: A role for PDK1 in acquired resistance to CDK4/6 inhibitors
Dana-Farber Cancer Inst: Consequences of centrosome amplification in breast cancer
H. Lee Moffitt Cancer Center: Targeting breast to bone metastases via bone seeking metalloproteinase inhibitors
Children’s Hospital Boston: Characterizing the anti-tumorigenicity, structure and biochemistry of proBMPs.
Duke Univ: The role of Cholesterol Metabolits in the Estrogen receptor signaling pathway
Duke Univ: Biomechanical profiling as a biomarker for breast cancer progression
Harvard: Cell-cell adhesion and Yap networks regulating tumor growth and invasion